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Abstract: Obesity may aggravate the effects of sarcopenia on skeletal muscle structure and function
in the elderly, but no study has attempted to identify the gene variants associated with sarcopenia in
obese women. Therefore, the aims of the present study were to: (1) describe neuromuscular function
in sarcopenic and non-sarcopenic women with or without obesity; (2) identify gene variants associ-
ated with sarcopenia in older obese women. In 307 Caucasian women (71 ± 6 years, 66.3 ± 11.3 kg),
skeletal muscle mass was estimated using bioelectric impedance, and function was tested with
a 30 s one-leg standing-balance test. Biceps brachii thickness and vastus lateralis cross-sectional
area (VLACSA) were measured with B-mode ultrasonography. Handgrip strength, maximum vol-
untary contraction elbow flexion (MVCEF), and knee extension torque (MVCKE) were measured
by dynamometry, and MVCKE/VLACSA was calculated. Genotyping was performed for 24 single-
nucleotide polymorphisms (SNPs), selected based on their previous associations with muscle-related
phenotypes. Based on sarcopenia and obesity thresholds, groups were classified as sarcopenic obese,
non-sarcopenic obese, sarcopenic non-obese, or non-sarcopenic non-obese. A two-way analysis of
covariance was used to assess the main effects of sarcopenia and obesity on muscle-related pheno-
types and binary logistic regression was performed for each SNP to investigate associations with
sarcopenia in obesity. There were no significant obesity * sarcopenic status interactions for any of the
investigated muscle-related phenotypic parameters. Neither sarcopenia nor obesity had a significant
effect on biceps brachii thickness, but sarcopenia was associated with lower VLACSA (p = 0.003).
Obesity was associated with lower MVCEF (p = 0.032), MVCKE (p = 0.047), and MVCKE/VLACSA
(p = 0.012) with no significant effect of sarcopenia. Adjusted for age and height, three SNPs (ACTN3
rs1815739, MTHFR rs1801131, and MTHFR rs1537516) were associated with sarcopenia in obese
participants. Sarcopenia was associated with a smaller muscle size, while obesity resulted in a lower
muscle quality irrespective of sarcopenia. Three gene variants (ACTN3 rs1815739, MTHFR rs1801131,
and MTHFR rs1537516) suspected to affect muscle function, homocysteine metabolism, or DNA
methylation, respectively, were associated with sarcopenia in obese elderly women. Understanding
the skeletal muscle features affected by sarcopenia and obesity, and identification of genes related
to sarcopenia in obese women, may facilitate early detection of individuals at particular risk of
sarcopenic obesity.
Keywords: elderly; sarcopenic obese; neuromuscular; single-nucleotide polymorphisms
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1. Introduction
Ageing is associated with an increase in visceral and intramuscular fat [1] and a
decrease in skeletal muscle mass [2]. The co-existence of low muscle mass and higher
fat is termed sarcopenic obesity (SO) [3], a condition that is most prevalent in the older
populations [4], particularly in women [5]. Sarcopenia and obesity are interlinked and
share some common pathophysiology. For instance, both are related to hormonal alteration,
low physical activity, elevated oxidative stress and pro-inflammatory cytokines, and insulin
resistance [6]. It has been suggested that the synergistic effect of sarcopenia and obesity in
SO exacerbates the condition compared to sarcopenia or obesity alone [7,8]. This has been
evidenced through the higher all-cause mortality in SO than sarcopenia or obesity alone in
men [9] and the aggravated detrimental effect on physical performance [10].
The prevalence of SO can range from 3.6 to 94.0% in the same population of elderly
women depending on the applied sarcopenia and obesity thresholds/indices [11], an issue
that plagues many study definitions [12]. Lower handgrip strength (HGS) is an initial
confirming diagnosis of sarcopenia [13]. SO studies that define sarcopenia through lower
HGS and muscle mass show a better prediction of physical capacity/functional status in
an elderly population [14–17], compared to studies using a lower muscle mass threshold
alone [18–21]. Similarly, in the context of obesity identification, the threshold of percentage
body fat (BF%) may be more valid than body mass index (BMI) as BMI may not change no-
ticeably in some cases, despite a significant change in muscle and fat mass with ageing [22].
Therefore, the inclusion of thresholds for lower muscle strength together with lower muscle
mass to detect sarcopenia, and use of percentage of adiposity in obesity classifications,
may best distinguish between non-sarcopenic non-obese, sarcopenic, obese, and SO older
people [23,24]. Despite the inconsistency in SO definitions, SO has been associated with
limitations to perform activities of daily living [3], metabolic disorders [25], cardiovascular
diseases (CVDs) [9], physical performance [26] impaired pulmonary function [27], and
increased risk of all-cause mortality [28].
In the elderly, impairments in neuromuscular function are likely dependent on the
severity of muscle wasting and obesity. For instance, the impact of loss of muscle mass
on muscle function is well established [29,30], and similarly obesity is known to impact
neuromuscular function negatively in the elderly [31,32]. The fact that some elderly people
are SO while others are not suggests that SO is the consequence of the interplay between
factors that influence both muscle and obesity related phenotypes, such as physical activity,
diet, sedentary behavior, and genetics [33–35]. Several studies have associated single-
nucleotide polymorphisms (SNPs) with muscle mass and strength in the elderly [36,37],
and recently our group found that sarcopenia in elderly women was associated with
polymorphisms in FTO, TRHR, ESR1, and NOS3 [38]. Similarly, adiposity and obesity
measures have been associated to SNPs such as FTO and PPARG2 in the elderly [39].
Yet, the interrelation of SNPs and SO has not been investigated. Since sarcopenia and
obesity each have been associated with adverse outcome measures in the elderly [40,41], an
assessment of the modulating role of gene variants should include sarcopenia and obesity
groups alongside an SO group. The aim of the present study was therefore to: (1) describe
neuromuscular function in sarcopenic and non-sarcopenic women with or without obesity,
and (2) identify gene variants associated with sarcopenia in obese elderly women.
2. Methodology
2.1. Participants
Elderly women (n = 307, aged 71 ± 6 years) were recruited from community groups
in England, such as the University of Third Age (U3A) and from word-of-mouth contacts.
The participants were 60+ years, free from any issues that affected their daily activities and
physical independence, and had no known neuromuscular or cardiovascular disorders.
Informed consent was collected from participants. Study protocols for the project followed
the Declaration of Helsinki guidelines and were approved by the ethics committee of
Manchester Metropolitan University.
J. Clin. Med. 2021, 10, 4933 3 of 13
2.2. Procedures
Procedures for body composition, muscle size, functional tests, and genotyping are
described in detail elsewhere [38,42], with a brief overview provided below.
2.3. Body Composition and Muscle Size
Bio-impedance analysis (Bodystat 1500MDD, Isle of Man, UK) was used to estimate
the skeletal muscle mass (SMM) and BF% of the participants [38]. Adhesive electrodes were
connected to the dorsum of the right hand and leg with participants in a supine position.
SMM was estimated with a previously validated equation [43] and BF% was recorded.
Skeletal muscle index (SMI) was calculated as SMM/height2 where height is in m.
Biceps brachii thickness was measured by ultrasound (MyLab™Twice, Esaote Biomed-
ical, Genoa, Italy). In short, the participants were asked to relax and hang their dominant
arm at their side and then the sagittal plane ultrasound scan was performed at 60% length
from the proximal end of the humerus [44]. Mean muscle thickness was measured with
digitizing software (ImageJ 1.45, National Institute of Health, Bethesda, MD, USA) at three
sites [45] (proximal, middle, and distal ends of the captured image) and recorded as biceps
brachii thickness.
To assess the anatomical cross-sectional area of the vastus lateralis muscle (VLACSA),
the same ultrasound was used to scan in a transverse plane at 50% of VL length. During
the procedure, the ultrasound probe was moved gently over the echo-absorptive markers
(placed from medial to lateral border of muscle) with minimal pressure applied, and the
scan was recorded as a video file. The recorded video was split into different individual
images, and the entire VLACSA was reconstructed by combining the individual images
between the contiguous intervals between each shadow cast by markers. For the measure-
ment, digitizing software (ImageJ 1.45, National Institute of Health, Bethesda, MD, USA)
was used to draw around the visible aponeurosis of the reconstructed VL to estimate ACSA.
The reliability and validity of this method were previously reported as high (ICC > 0.99)
when compared with MRI [46].
2.4. Muscle Strength and Quality Measurement
Handgrip strength (HGS) was measured for both the right and left hands with a
dynamometer (JAMAR plus, JLW Instruments, Chicago, IL, USA). Three trials were per-
formed with each hand and the highest value from either hand was recorded [38]. The ICC
of HGS with this procedure is 0.99 [47].
For the measurement of maximum voluntary contraction elbow flexion torque (MVCEF)
and maximum voluntary contraction knee extension torque (MVCKE), a customized dy-
namometer with a load cell (Zemic, Eten-Leur, the Netherlands) was used. Both procedures
were performed on the participant’s dominant side, identified by self-report. MVCEF was
performed at 60◦ flexion (0◦ is a straight position). Three trials were performed and the
maximum of the three attempts was recorded and converted to MVCEF torque as:
MVCEF = Force × Radius length × Cos30◦
Similarly, three trials were used to assess MVCKE at 120◦ knee extension (180◦ is a full
knee extension) with MVCKE torque calculated from the highest value as:
MVCKE = Force × (distance from rotation point of dynamometer to ankle strap) × Cos30◦
Subsequently, lower-limb muscle quality was defined as the knee strength relative to
VLACSA (MVCKE/VLACSA).
2.5. One-Leg Standing-Balance Test
As a measure of balance and for the purposes of classifying participants (see statistics
part below), the one-leg standing-balance test (OLST) was performed barefoot on the right
leg regardless of dominance, consistent with previous studies [48,49]. Participants were
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instructed to stand straight, with their left knee flexed at ~90◦, for up to a maximum of
30 s. Participants completed up to three attempts if they failed to achieve 30 s, and the
maximum time achieved was recorded as their OLST score [50].
2.6. Selection of Single-nucleotide Polymorphisms, Sample Collection, DNA Extraction
and Genotyping
A total of 24 SNPs were selected for the present study (Supplementary Table S1)
based on a number of reasons, including the presence of extant literature associating those
SNPs with similar phenotypes (even if in different populations), and the likelihood of
affecting relevant muscle phenotypes via transcriptional differences as reported in previous
studies. Some SNPs were also included due to conflicting results regarding associations
with relevant phenotypes.
Blood or saliva samples were collected for genetic analysis. A QIAcube robot, QIAamp
DNA Blood Mini kit, and standard spin column protocol (Qiagen, Crawley, UK) were
used to isolate DNA from the collected samples. A Fluidigm EP1 system (Fluidigm,
Cambridge, UK) was used for initial genotyping of the 24 SNPs. When there was an
error (such as no agreement between duplicates), a StepOnePlus (Applied Biosystems®,
Paisley, UK) was later used. The PCR conditions using the EP1 followed the manufacturer’s
instructions. In short, the thermocycling protocol was an initial 120 s at 95 ◦C followed
by 45 cycles of denaturation for 2 s at 95 ◦C and then annealing and extension for 20 s
at 60 ◦C. Genotypes were identified based on end-point fluorescence, whereby TaqMan
assays (Applied Biosystems, Paisley, UK) included VIC® and FAM® dyes for all SNPs.
Similarly, for the StepOnePlus, the thermocycling conditions were an initial 20 s at 95 ◦C
followed by 50 cycles of denaturation for 3 s at 95 ◦C, then annealing and extension for
20 s at 60 ◦C. Genotyping and interpretation were based on intensity of VIC® and FAM®
intensity and visualization was performed using cluster plots.
3. Statistics
SPSS 26.0 (SPSS, Chicago, IL, USA) was used for all analyses. Participants were
characterized into four non-overlapping groups based on thresholds for sarcopenia and
obesity. Sarcopenia was defined as an SMI < 6.76 kg/m2 [51] and lower HGS as suggested
by EWGSOP [52]. Receiver operating curve (ROC) analysis was performed to determine
the sarcopenic threshold for lower HGS based on an OLST balance of <5 s [53]. This
resulted in a good classification (AUC = 0.80) of lower HGS with OLST and identified the
HGS threshold of 28.35 kg (~28.5 kg) (sensitivity 65%, specificity 82%) as a measure of low
muscle strength. Obesity was defined as BF% > 38% [28].
Based on the above thresholds for sarcopenia and obesity, SO individuals were de-
fined as those with SMI < 6.76 kg/m2, HGS < 28.5 kg and BF% > 38%. Non-sarcopenic
obese were defined as individuals who were non-sarcopenic (either SMI ≥ 6.76 kg/m2 or
HGS > 28.5 kg or both) but had BF% > 38%. Sarcopenic non-obese were defined as indi-
viduals who were sarcopenic (SMI < 6.76 kg/m2 and HGS < 28.5 kg) and had BF% ≤ 38%.
The non-sarcopenic non-obese group was defined as individuals who were non-sarcopenic
(either SMI ≥ 6.76 kg/m2 or HGS > 28.5 kg or both) and had BF% ≤ 38%. The classifica-
tion of participants into four groups is shown in Figure 1 and adopted an approach used
previously [5,18,54].
A Shapiro–Wilk test was performed to test whether the data were normally dis-
tributed. Variables that were not normally distributed (biceps brachii thickness, MVCEF,
and MVCKE/VLACSA) were log-transformed before further statistical analysis. To identify
covariates, Pearson correlation coefficients were calculated between age and height, and
body composition indices (BF% and SMI). A two-way analysis of covariance (ANCOVA)
was used to assess the main effects of sarcopenia and obesity on muscle-related phenotypic
outcome measures, where a sarcopenia * obesity interaction would indicate that the effects
of sarcopenia differed between the obese and non-obese, or that the effect of obesity was
different in sarcopenic and non-sarcopenic women.
J. Clin. Med. 2021, 10, 4933 5 of 13




Figure 1. Flowchart showing the classification of participants into four categories: sarcopenic-obese, non-sarcopenic obese, 
sarcopenic non-obese, and non-sarcopenic non-obese groups. Abbreviations: SMI, skeletal muscle index; HGS, handgrip 
strength; BF%, body fat percent. 
A Shapiro–Wilk test was performed to test whether the data were normally distrib-
uted. Variables that were not normally distributed (biceps brachii thickness, MVCEF, and 
MVCKE/VLACSA) were log-transformed before further statistical analysis. To identify co-
variates, Pearson correlation coefficients were calculated between age and height, and 
body composition indices (BF% and SMI). A two-way analysis of covariance (ANCOVA) 
was used to assess the main effects of sarcopenia and obesity on muscle-related pheno-
typic outcome measures, where a sarcopenia * obesity interaction would indicate that the 
effects of sarcopenia differed between the obese and non-obese, or that the effect of obesity 
was different in sarcopenic and non-sarcopenic women. 
Binary logistic regression was performed for each individual SNP using the covari-
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Figure 1. Flowchart showing the classification of participants into four categories: sarcopenic-obese, non-sarcopenic obese,
sarcopenic non-obese, and non-sarcopenic non-obese groups. Abbreviations: SMI, skeletal muscle index; HGS, handgrip
strength; BF%, body fat percent.
Binary logistic regression was performed for each individual SNP using the covariates
to investigate their association with sarcopenia in the obese elderly. Where p < 0.15, the rarer
homozygotes were combined with heterozygotes (in both dominant and recessive models)
and two-group analysis was performed. Similarly, when very few participants were in
one of the homozygous groups, the group was combined with the heterozygotes [55].
Odds ratio (OR) was used to estimate effect size for significant SNP-groups associations.
In all analyses, p < 0.05 was considered significant. Only significant SNP associations
are reported.
4. Results
4.1. General Characteristics, Prevale ce, and Differences i Muscle Size, Strength, and Quality
among Groups
The prev lence f sarcope ic-obese, non-sarcopenic obese, sarcopenic non-obese, and
no - arcope ic non-ob se groups was 25.1%, 57.3%, 2.3%, and 15.3%, respectively, in the
present elderly women. There ere ignificant diff rences in age, height, body mass, BMI,
SMI, HGS, OLST, and BF% between the gr ups (Table 1).
There wer significant correlations between BF% and age (r = 0.290, p <0.001), and
BF% and height (r = −0.250, p < 0.001). Table 2 shows the data on muscle size and strength.
There was no significant obesity * sarcopenic status interaction for any of the investigated
muscle-related phenotypic parameters, indicating that the effect of sarcopenia did not
differ according to obesity status, and that the effect of obesity did not differ according to
sarcopenia status. There was no significant impact of obesity and sarcopenia on biceps
brachii thickness (p > 0.05). Sarcopenia was associated with lower VLACSA (p = 0.003), but
there was no significant effect of obesity (p = 0.074). Obesity was associated with a lower
MVCEF (p = 0.032), MVCKE (p = 0.047), and MVCKE/VLACSA (p = 0.012) with no significant
effect of sarcopenia on these parameters (p > 0.05).
J. Clin. Med. 2021, 10, 4933 6 of 13
















Age (years) 70.7 (70.1–71.4) 72.5 (71.3–73.8) 4 70.8 (70.0–71.7) 4 68.7 (65.2–72.2) 67.6 (66.3–69.0) 1,2
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(3.48–4.30) 0.012 0.077 0.156
Abbreviations: VLACSA, vastus lateralis anatomical cross-sectional area; MVCEF, maximum voluntary contraction elbow flexion torque;
MVCKE, maximum voluntary contraction knee extension torque. Data are means (95% CI). 1,2,3,4 indicate difference from sarcopenic obese,
non-sarcopenic obese, sarcopenic non-obese and non-sarcopenic non-obese, respectively at p ≤ 0.05. *, standard in statistical notation to
denote interaction between the grouping variables.
4.2. Associations of Gene Variants with Sarcopenia in Obese Elderly Women
The genotyping success rate was > 99% in the obese subgroups (n = 77 + 176). All
genotype distributions were in Hardy–Weinberg equilibrium (p > 0.05). Among the 24 SNPs,
three were associated with sarcopenia: ACTN3 rs1815739, MTHFR rs1801131, and MTHFR
rs1537516 (Table 3) in obese elderly. The genotype distribution of these three SNPs is shown
in Supplementary Table S2.
Table 3. Association of single-nucleotide polymorphisms with sarcopenia in obese women.
SNPs B S.E (β) Wald’s χ2 p OR 95% CI Risk Genotypes
ACTN3 rs1815739 0.612 0.294 4.341 0.037 1.84 1.04–3.28 CC
MTHFR rs1801131 0.614 0.291 4.470 0.034 1.85 1.05–3.27 GG + GT
MTHFR rs1537516 1.011 0.341 8.811 0.003 2.75 1.41–5.36 AA + AG
Binary logistic regression adjusted for age and height showed that ACTN3 rs1815739
CC homozygotes had 1.8 times the odds of being in the sarcopenic group than T-allele
carriers (OR = 1.84, 95% confidence interval [CI] = 1.04–3.28, p = 0.037) in an obese popula-
tion. MTHFR rs1801131 G-allele carriers had 1.9 times the odds of being sarcopenic than
TT homozygotes (OR = 1.85, 95% CI = 1.05–3.27, p = 0.034) among obese elderly. Similarly,
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MTHFR rs1537516 A-allele carriers had 2.8 times the odds of being sarcopenic than GG
homozygotes (OR = 2.75, 95% CI 1.41–5.36, p = 0.003, Table 3) in obese elderly women.
5. Discussion
The present study showed that sarcopenia was associated with lower-limb muscle
atrophy, while obesity was associated with reduced upper/lower-limb muscle strengths.
Obesity, but not sarcopenia, was associated with lower muscle quality. We also identified
that within the 253 obese elderly women, there were three SNPs that were associated with
sarcopenia, namely, ACTN3 rs1815739, MTHFR rs1801131, and MTHFR rs1537516. Expand-
ing the knowledge of the impact of polymorphisms on skeletal muscle phenotypes during
sarcopenia and obesity in elderly women may help in early identification of individuals at
particular risk of sarcopenic obesity.
The 25% prevalence of SO observed in the present elderly population is consistent
with other studies reporting SO prevalence across different populations [27,28,56–58].
However, it should be noted that, despite similar SO prevalence, studies have used different
indices of sarcopenia and obesity classification, which can result in a prevalence of SO in
a given population being 4% or even as high as 94% depending on the sarcopenia and
obesity definitions/thresholds used [11]. The present study was the first to investigate
the association of muscle size, strength, and quality measures in different groups, ranging
from non-sarcopenic non-obese to sarcopenic obese. Although we did not observe any
effect of sarcopenia and obesity on biceps brachii thickness in the present elderly women,
sarcopenia was associated with lower VLACSA. This association of sarcopenia with lower
VLACSA reflects the muscle atrophy in terms of mass/size in sarcopenic individuals [59,60].
We observed in elderly women that obesity is associated with a reduction in upper-limb
(MVCEF) and lower-limb (MVCKE) muscle strength. This is somewhat surprising as most
studies report a higher muscle strength in obese [32,61]. We have no explanation for this
unexpected finding, but we did see a lower MVCKE/VLACSA reflecting a lower muscle
quality that has regularly been reported in obesity [62,63] and has been suggested to be
due to accumulation of intramuscular fat, impaired muscle activation [32], and systemic
inflammation [32,64]. Our findings suggest that obesity causes a reduced muscle quality,
even in non-sarcopenic older women. The reduction in muscle function has been previously
associated with an increased risk of falls [65] and disability in activities of daily living [66].
Few studies have attempted to identify the genes associated with sarcopenia [38,67–69].
It should be noted that the SNPs showing associations in the present study (ACTN3
rs1815739, MTHFR rs1801131, and MTHFR rs1537516) are different from our previous
study that identified associations of FTO, TRHR, ESR1, and NOS3 gene variants with
sarcopenia [38]. A possible explanation is that the previous study used a different definition
of sarcopenia [38]. The present study identified elderly women with obesity who were
ACTN3 rs1815739 RR homozygotes to be at a nearly-2-fold higher risk of sarcopenia
than X-allele carriers. This association is consistent with a previous study that observed
female > 75-year-old R-allele carriers had a 2.8-fold higher risk of sarcopenia [69], but
differs from another study that reported XX as the risk genotype for sarcopenia in older
men and women [70]. ACTN3 rs1815739 has been widely studied with skeletal muscle
phenotypes in different populations, with varying results [71]. Although the ACTN3 R
allele mostly favors better athletic (sprint) performance [72] and higher muscle mass and
strength phenotypes [73], there are also studies that have reported the X allele as beneficial
for fat-free mass in older people or peak power in non-athletic populations [74,75]. The
putative effect of ACTN3 genotype has also shown different results at baseline and post
training. For instance, XX homozygotes had greater knee extensor peak strength while the
gain after the training was greater for RR homozygotes in women [75]. Despite this ACTN3
rs1815739 X where the arginine (position 577) is replaced by a premature stop codon, there
is no evidence that the deficit of alpha-actinin directly causes muscle-related disease [76],
although recent evidence suggests a potential modulating role [77]. Furthermore, ACTN3
X as a beneficial allele is also consistent with a previous association with longevity [78] and
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improved oxidative metabolism in ACTN3 knockout mice [79]. Thus, the relationships of
ACTN3 rs1815739 with muscle performance and health-related phenotypes are complex
and seem dependent on context including population type.
The current study was the first to find an association of MTHFR gene variants
(rs1537516 and rs1801131) with risk factors for sarcopenia in obese elderly women. MTHFR
rs1537516 A-allele carriers had a >2-fold higher risk than GG homozygotes. As MTHFR
plays an important role in methylation and thus in epigenetic control [80], the association
of rs1537516 with sarcopenia in an obese population may occur via post-transcriptional
regulation. However, we urge future studies to investigate the functional relevance of this
SNP with sarcopenia. The minor A allele has been previously observed as a risk factor for
higher diastolic blood pressure [81]. Similarly, MTHFR rs1801131 G-allele carriers had a
1.8-fold higher risk of sarcopenia than TT homozygotes in our elderly female population.
Although the GG genotype was advantageous for speed and strength performance in
young Russian and Polish athletes [82], our observation may be explained by the associa-
tion of the GG genotype with higher plasma homocysteine concentration [83]. Previous
studies have associated elevated homocysteine with lower physical activity [84] and muscle
strength [85]—characteristics observed in sarcopenic populations [52,86].
It is established that the degree and severity of sarcopenia and obesity increases with
age [13,87], despite individual differences related to favorable gene variants as well as
dietary or exercise habits. Unlike research into athletic performance, where age at the
time of sampling does not affect analysis of associations with elite performance while
young [88], comparable studies of the elderly may be affected by participant age due to
additional associations with longevity and health status. Accordingly, we acknowledge
that there was likely to be a selection bias in the current study as we recruited elderly
women who were still the healthiest of those within the broader population living indepen-
dently. However, we suspect that studying elderly women who are more impaired would
only stress the extremes of our phenotypes, potentially exposing more and/or stronger
genetic associations.
Although the use of an adiposity threshold for the categorization of obesity is com-
monly used [23,24], the thresholds for sarcopenia are still debatable and responsible for
population variance in prevalence [38,89]. In the present study, sarcopenia was defined by
HGS and muscle mass cut-offs in line with EWGSOP [52]. We should however acknowl-
edge that our novel approach to establishing a low HGS threshold adopted a functional
threshold of OLST < 5 s. In contrast to others who have used a gait speed threshold of
0.8 m/s [90,91], we suggest our approach of using a standing balance threshold is also
valid as it was able to make a good prediction for HGS (AUC = 0.80) with sensitivity of
65.0 and specificity of 82.0, when compared with a previous study that showed sensitivity
of 76.9 and specificity of 62.5 using gait speed threshold [90].
The current study has some other limitations. Firstly, participants were distributed
unevenly between groups, meaning the sarcopenic non-obese group possessed few par-
ticipants. This uneven group distribution could be overcome with a larger population
group. Based on a power analysis for MVCEF, we would need at least 21 people in a
group to detect a 23.4% difference between groups with an α < 0.05 and a β > 0.80. Our
overall sample size would exceed n = 900. Secondly, one needs to be cautious to extend
our observations to men, as the current study is focused on elderly women, although it is
likely that the action of most gene variants will not differ between men and women. Our
decision to limit the investigation to a single sex can be justified by the earlier onset of
sarcopenia-related problems with daily life in women than men [92]. The same argument
applies to the fact that we only studied Caucasians, and findings may not be generalized
to people with different geographic ancestry. We contend that this is a limitation of ex-
trapolation of results, rather than a real limitation of method, as the genetic differences
between people within a geographic ancestry group are larger than the typical genetic
differences between geographic ancestry groups [93]. The current study used BIA for the
estimation of skeletal muscle mass, a technique that is reported to overestimate skeletal
J. Clin. Med. 2021, 10, 4933 9 of 13
muscle mass by 0.6 kg in the elderly [94]. Despite this shortcoming we used BIA as it is a
cheap, accessible and radiation-free method that has been validated with DXA [95], and
adopted on numerous occasions for large population studies of elderly muscle mass [96,97].
Finally, this investigation was limited to the 24 studied SNPs, and in fact it is likely that
many other SNPs and other types of genetic variants, which we did not investigate, are
also associated with the phenotypes we assessed.
6. Conclusions
Lower-limb muscle atrophy is a characteristic of sarcopenia, while obesity in older
women was associated with lower upper- and lower-limb muscle strength. Three gene
variants (ACTN3 rs1815739, MTHFR rs1801131, and MTHFR rs1537516) previously re-
ported to affect muscle function, homocysteine metabolism, or suspected to affect DNA
methylation, were associated with sarcopenia in obese elderly women. Understanding
the neuromuscular features of sarcopenia and obesity and genes related to sarcopenia
in obese elderly women may facilitate early detection of individuals at particular risk of
sarcopenic obesity.
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